Prebiotic oligosaccharides for peanut allergy prevention and treatment

Overview

This research program investigates the use of prebiotic oligosaccharides, specifically pure galactooligosaccharides (GOS) and lactosamine-enriched humanized GOS (hGOS), to prevent and treat peanut allergy. Peanut allergy is the most common food allergy in children, and this work targets a critical unmet need in food allergy management. The approach leverages the connection between gut barrier function, microbiome composition, and immune system regulation to reduce allergic responses.

The solution works through multiple mechanisms: strengthening intestinal barrier function by enhancing goblet cell activity and increasing MUC2 expression, modulating the gut microbiome to increase beneficial bacteria such as Akkermansia and Bifidobacterium, and stimulating Galectin-1 (Gal-1) expression, which regulates T cell responses and reduces pro-allergic inflammation.

Technical specifications

Research model:

• CC027/GeniUnc mouse model validated as reactive to oral peanut challenge
• Mice sensitized weekly with peanut protein (2 mg for two weeks, then 5 mg in week three)
• Oral challenge protocol to assess allergic reactions

Key biological targets:

• Peanut-specific IgE levels
• Gut permeability measurements
• Anaphylaxis reaction severity
• Microbiome profiling via whole genome shotgun (WGS) sequencing
• Th1, Th2, and Th17 cytokine quantification
• Galectin-1 (Lgals1) expression and functional analysis

Mechanism of action:

• GOS strengthens intestinal barrier function through enhanced goblet cell activity
• Increases MUC2 expression and decreases intestinal permeability
• Stimulates Lgals1 expression encoding Galectin-1, which modulates T cell interactions
• LacNAc-enriched GOS increases relative abundance of Akkermansia and Bifidobacterium
• Shifts T cell profiles away from pro-allergic Th2 responses

Validation approach:

• Lgals1-deficient mice studies to confirm Gal-1 role in prebiotic-mediated protection
• Comparative testing of GOS versus hGOS for prevention and treatment efficacy
• Microbiome correlation analysis with decreased gut permeability

Technology readiness level

This research is at an early-to-mid stage of preclinical validation. Preliminary data has demonstrated proof of concept: GOS-fed, peanut-sensitized mice showed significant increases in Akkermansia and Bifidobacterium, along with non-statistically significant protective trends in peanut-specific IgE, anaphylaxis reaction severity, and intestinal permeability. The research team has established the CC027/GeniUnc mouse model as a reliable platform for peanut allergy studies.

Next-phase validation will confirm efficacy of both GOS and hGOS formulations, elucidate the mechanistic role of Galectin-1, and identify microbiome signatures associated with reduced gut permeability and allergic outcomes. The work is positioned to advance toward potential translational studies and partnership opportunities for prebiotic-based allergy interventions.